Findings

What do systematic reviews say?

38 questions · 38 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 2.6%GRADE not reported 0 · 0%Very low 8 · 21.1%Low 6 · 15.8%Moderate 13 · 34.2%High 10 · 26.3%

Atypical vs atypical antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
High

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Atypical vs atypical antipsychotics (only short term)

No improvement (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Moderate

Atypical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Atypical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical vs typical antipsychotics (only short term)

Worse or no improvement · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Low

Atypical vs typical antipsychotics (only short term)

Adverse effects ‐ anticholinergic effects · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

No response · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 255 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Symptomatic hyperprolactinaemia · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Use of antiparkinsonian medications · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High